Correction to: Can We Accurately Predict Cost Effectiveness Without Access to Overall Survival Data? The Case Study of Nivolumab in Combination with Ipilimumab for the Treatment of Patients with Advanced Melanoma in England
Crossref DOI link: https://doi.org/10.1007/s41669-018-0096-x
Published Online: 2018-09-11
Published Print: 2019-03
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Lee, D.
Amadi, A.
Sabater, J.
Ellis, J.
Johnson, H.
Kotapati, S.
McNamara, S.
Walker, A.
Cooper, M.
Patterson, K.
Roskell, N.
Meng, Y.
Text and Data Mining valid from 2018-09-11
Article History
First Online: 11 September 2018